Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 ...
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to ...
Inogen beat Q4 earnings and revenue estimates, citing strong B2B demand. Analysts see potential but flag supply challenges and restructuring risks. Inogen, Inc. (NASDAQ: INGN) is well-poised for ...
Inogen posted a Q4 adjusted EPS loss of $0.24, beating estimates, with sales reaching $80.1 million versus the $73.9 million consensus. The company expects FY25 revenue of $352 million-$355 ...
GOLETA, Calif. (AP) — GOLETA, Calif. (AP) — Inogen Inc. (INGN) on Tuesday reported a loss of $9.8 million in its fourth quarter. The Goleta, California-based company said it had a loss of 41 ...
For the quarter ended December 2024, Inogen (INGN) reported revenue of $80.08 million, up 5.5% over the same period last year. EPS came in at -$0.41, compared to -$1.14 in the year-ago quarter.
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results